Developed in collaboration with Waters and Labcyte, the platform enables applications including high-throughput drug screening and metabolomic profiling.
Driven by strong pharma sales, revenues increased to $715 million from $687 million in Q4 2017, besting the consensus analyst estimate of $703 million.
The company's revenues were up, but fell short of Wall Street estimates as growth in the European market was hampered by lower sales to pharma customers there.
Waters said the acquisition is part of a strategy to develop simpler, more streamlined mass spec workflows that will be accessible to non-expert users.
The company posted Q2 revenues of $596.2 million, up from $558.3 million in Q2 2017, short of the average Wall Street estimate of $598 million.
As part of the deal, Waters has also placed a Synapt G2-Si mass spec instrument at Purdue University to help advance research applications for DESI.
Major releases were relatively sparse at ASMS as many vendors focused instead on the development of applications and workflows for their existing platforms.
Positive first quarter earnings reports lifted many stocks of life science tools firms even as the broader biotechnology market suffered.
Organic revenues were up 2 percent, as the company saw solid demand among its pharma customers but a decline in sales of its mass spectrometry instruments.
Two researchers are calling for education for scientists on defending facts.
Researchers were among those who marched in London this weekend to call for another vote on Brexit.
Duke has agreed to pay $112.5 million to settle a lawsuit regarding its handling of data falsified by biologist Erin Potts-Kant.
In PLOS this week: genetic factors influencing inorganic arsenic metabolism and toxicity, a germline variant in the cell adhesion molecule-coding gene DSCAM, and more.